Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Saturday, March 5, 2016
"Prescription drug spending growth is projected to slow down to an average 6.3% annual growth from 2015 through 2024 because of improving economic conditions, changes in benefit management designed to encourage better drug adherence for people with chronic health conditions, and anticipated changing clinical guidelines designed to encourage drug therapies at earlier stages of treatment, according to the Centers for Medicare & Medicaid Services. In looking at the recent surge in medication spending, many factors played a role, including prices escalating for brand medications and the ongoing increase in utilization of specialty therapies, including rapid uptake of new hepatitis C therapies and expensive compounded therapies, says Jonathan C. Roberts, president, CVS/Caremark, and executive vice president, CVS Health, Woonsocket, Rhode Island."
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment